The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Official Title: Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab Therapy
Study ID: NCT00431067
Brief Summary: The primary objective of this trial is to explore the efficacy of BIBW 2992 in HER2 positive metastatic breast cancer patients after failure of trastuzumab containing regimens.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
1200.11.3 Boehringer Ingelheim Investigational Site, Scottsdale, Arizona, United States
1200.11.7 Boehringer Ingelheim Investigational Site, Encinitas, California, United States
1200.11.4 Boehringer Ingelheim Investigational Site, Santa Monica, California, United States
1200.11.2 Boehringer Ingelheim Investigational Site, Tampa, Florida, United States
1200.11.1 Boehringer Ingelheim Investigational Site, Boston, Massachusetts, United States
1200.11.5 Boehringer Ingelheim Investigational Site, Chapel Hill, North Carolina, United States
1200.11.4401 Boehringer Ingelheim Investigational Site, Bournemouth, , United Kingdom
1200.11.4402 Boehringer Ingelheim Investigational Site, Crownhill, Plymouth, , United Kingdom
1200.11.4406 Boehringer Ingelheim Investigational Site, Guildford, , United Kingdom
1200.11.4405 Boehringer Ingelheim Investigational Site, London, , United Kingdom
1200.11.4404 Boehringer Ingelheim Investigational Site, Poole, , United Kingdom
1200.11.4403 Boehringer Ingelheim Investigational Site, Truro, , United Kingdom
Name: Boehringer Ingelheim
Affiliation: Boehringer Ingelheim
Role: STUDY_CHAIR